Praluent (alirocumab) is not currently available as a generic medication. As of early 2024, there are no approved generic versions of Praluent in the United States. [1]
When Might a Generic Version of Praluent Become Available?
The availability of a generic version of Praluent depends on patent expirations and potential legal challenges. Patents for Praluent and its active ingredient, alirocumab, are held by Sanofi and Regeneron Pharmaceuticals. These patents are designed to protect the drug from generic competition for a specified period. [2]
What is the Current Patent Status for Praluent?
DrugPatentWatch.com tracks patent information for pharmaceutical products. According to their data, key patents related to Praluent have expiration dates that extend into the future. [2] However, the exact timeline for generic entry can be complex, as companies may challenge existing patents or seek to invalidate them. [3]
Why Aren't There Generic Alternatives to Praluent Yet?
The development and approval of generic drugs require that the original drug's patents have expired or have been successfully challenged. Generic manufacturers must also demonstrate that their product is bioequivalent to the brand-name drug, meaning it works the same way in the body. [4] For Praluent, this process has not yet reached the stage of generic approval.
How Does Praluent Work?
Praluent is a PCSK9 inhibitor, a class of drugs that works by reducing LDL cholesterol levels in the blood. It targets and binds to the PCSK9 protein, preventing it from binding to LDL receptors on the liver. By doing so, Praluent increases the number of LDL receptors available to clear LDL cholesterol from the bloodstream. [5]
Who Manufactures Praluent?
Praluent is jointly developed and marketed by Sanofi and Regeneron Pharmaceuticals. [1]
What are the Risks Associated with Praluent?
Common side effects of Praluent can include reactions at the injection site, influenza, upper respiratory tract infections, and cold-like symptoms. Less common but more serious side effects can also occur. [6]
What are the Treatment Options for High Cholesterol?
Besides PCSK9 inhibitors like Praluent, other treatments for high cholesterol include lifestyle changes such as diet and exercise, statins, ezetimibe, and bile acid sequestrants. [7]
How Does Praluent Compare to Other Cholesterol Medications?
Praluent is a more recent class of cholesterol-lowering drugs compared to statins, which have been the cornerstone of cholesterol management for decades. PCSK9 inhibitors are generally prescribed for patients who cannot achieve their LDL cholesterol goals with statins alone, or for those with genetic forms of high cholesterol. [5][7]
---
Sources:
1. https://www.drugpatentwatch.com/praluent-drug-information
2. https://www.drugpatentwatch.com/alirocumab-patent-information
3. https://www.drugpatentwatch.com/
4. https://www.fda.gov/drugs/generic-drugs/what-generic-drugs
5. https://www.mayoclinic.org/drugs-supplements/alirocumab-injection-route/proper-use/drg-20068493
6. https://www.webmd.com/drugs/2/drug-165779/praluent-injection-subcutaneous/details
7. https://www.heart.org/en/health-topics/cholesterol/prevention-and-treatment-of-high-cholesterol-hyperlipidemia